IDO2 modulates t cell-dependent autoimmune responses through a b cell-intrinsic mechanism

Journal of Immunology

Volumn 196, Issue 11, 2016, Pages 4487-4497

  Merlo, Lauren M F ^a   DuHadaway, James B ^a   Grabler, Samantha ^a   Prendergast, George C ^a,b,c   Muller, Alexander J ^a,b,c   Mandik Nayak, Laura ^a  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; IDO2; INDOLEAMINE 2,3 DIOXYGENASE; UNCLASSIFIED DRUG; IDO2 PROTEIN, MOUSE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTHRITIS; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CONTACT ALLERGY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME DEFICIENCY; IMMUNOMODULATION; INFLAMMATION; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; UPREGULATION; ANIMAL; C57BL MOUSE; CELL CULTURE; DEFICIENCY; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; TRANSGENIC MOUSE;

ANIMALS; AUTOIMMUNITY; B-LYMPHOCYTES; CELLS, CULTURED; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; T-LYMPHOCYTES;

EID: 84975132545     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1600141     Document Type: Article

References (58)

1. Yuasa, H. J., K. Mizuno, and H. J. Ball. 2015. Low efficiency IDO2 enzymes are conserved in lower vertebrates, whereas higher efficiency IDO1 enzymes are dispensable. FEBS J. 282: 2735-2745.
2. Munn, D. H., M. Zhou, J. T. Attwood, I. Bondarev, S. J. Conway, B. Marshall, C. Brown, and A. L. Mellor. 1998. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281: 1191-1193.
3. Prendergast, G. C. 2008. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 27: 3889-3900.
4. Prendergast, G. C., M. Y. Chang, L. Mandik-Nayak, R. Metz, and A. J. Muller. 2011. Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases. Curr. Med. Chem. 18: 2257-2262.
5. Prendergast, G. C., C. Smith, S. Thomas, L. Mandik-Nayak, L. Laury-Kleintop, R. Metz, and A. J. Muller. 2014. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunol. Immunother. 63: 721-735.
6. Szántó, S., T. Koreny, K. Mikecz, T. T. Glant, Z. Szekanecz, and J. Varga. 2007. Inhibition of indoleamine 2,3-dioxygenase-mediated tryptophan catabolism accelerates collagen-induced arthritis in mice. Arthritis Res. Ther. 9: R50.
7. Fallarino, F., C. Volpi, T. Zelante, C. Vacca, M. Calvitti, M. C. Fioretti, P. Puccetti, L. Romani, and U. Grohmann. 2009. IDO mediates TLR9-driven protection from experimental autoimmune diabetes. J. Immunol. 183: 6303-6312.
8. Scott, G. N., J. DuHadaway, E. Pigott, N. Ridge, G. C. Prendergast, A. J. Muller, and L. Mandik-Nayak. 2009. The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. J. Immunol. 182: 7509-7517.
9. Mellor, A. L., and D. H. Munn. 2004. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4: 762-774.
10. Shinde, R., M. Shimoda, K. Chaudhary, H. Liu, E. Mohamed, J. Bradley, S. Kandala, X. Li, K. Liu, and T. L. McGaha. 2015. B Cell-Intrinsic IDO1 Regulates Humoral Immunity to T Cell-Independent Antigens. J. Immunol. 195: 2374-2382.
11. Metz, R., S. Rust, J. B. Duhadaway, M. R. Mautino, D. H. Munn, N. N. Vahanian, C. J. Link, and G. C. Prendergast. 2012. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. OncoImmunology 1: 1460-1468.
12. Ravishankar, B., H. Liu, R. Shinde, K. Chaudhary, W. Xiao, J. Bradley, M. Koritzinsky, M. P. Madaio, and T. L. McGaha. 2015. The amino acid sensor GCN2 inhibits inflammatory responses to apoptotic cells promoting tolerance and suppressing systemic autoimmunity. Proc. Natl. Acad. Sci. USA 112: 10774-10779.
13. Munn, D. H., M. D. Sharma, B. Baban, H. P. Harding, Y. Zhang, D. Ron, and A. L. Mellor. 2005. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22: 633-642.
14. Merlo, L. M., E. Pigott, J. B. DuHadaway, S. Grabler, R. Metz, G. C. Prendergast, and L. Mandik-Nayak. 2014. IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis. J. Immunol. 192: 2082-2090.
15. Metz, R., C. Smith, J. B. DuHadaway, P. Chandler, B. Baban, L. M. Merlo, E. Pigott, M. P. Keough, S. Rust, A. L. Mellor, et al. 2014. IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation. Int. Immunol. 26: 357-367.
16. Trabanelli, S., D. Ocadĺková, M. Ciciarello, V. Salvestrini, M. Lecciso, C. Jandus, R. Metz, C. Evangelisti, L. Laury-Kleintop, P. Romero, et al. 2014. The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells. J. Immunol. 192: 1231-1240.
17. Metz, R., J. B. Duhadaway, U. Kamasani, L. Laury-Kleintop, A. J. Muller, and G. C. Prendergast. 2007. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 67: 7082-7087.
18. Criado, G., E. Simelyte, J. J. Inglis, D. Essex, and R. O. Williams. 2009. Indoleamine 2,3 dioxygenase-mediated tryptophan catabolism regulates accumulation of Th1/Th17 cells in the joint in collagen-induced arthritis. Arthritis Rheum. 60: 1342-1351.
19. Sakurai, K., J. P. Zou, J. R. Tschetter, J. M. Ward, and G. M. Shearer. 2002. Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 129: 186-196.
20. Xu, H., T. B. Oriss, M. Fei, A. C. Henry, B. N. Melgert, L. Chen, A. L. Mellor, D. H. Munn, C. G. Irvin, P. Ray, and A. Ray. 2008. Indoleamine 2,3-dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammation. Proc. Natl. Acad. Sci. USA 105: 6690-6695.
21. Kouskoff, V., A. S. Korganow, V. Duchatelle, C. Degott, C. Benoist, and D. Mathis. 1996. Organ-specific disease provoked by systemic autoimmunity. Cell 87: 811-822.
22. Matsumoto, I., A. Staub, C. Benoist, and D. Mathis. 1999. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 286: 1732-1735.
23. Anolik, J. H. 2013. B cell biology: implications for treatment of systemic lupus erythematosus. Lupus 22: 342-349.
24. LaBranche, T. P., C. L. Hickman-Brecks, D. M. Meyer, C. E. Storer, M. I. Jesson, K. M. Shevlin, F. A. Happa, R. A. Barve, D. J. Weiss, J. C. Minnerly, et al. 2010. Characterization of the KRN cell transfer model of rheumatoid arthritis (KRNCTM), a chronic yet synchronized version of the K/BxN mouse. Am. J. Pathol. 177: 1388-1396.
25. Korganow, A. S., H. Ji, S. Mangialaio, V. Duchatelle, R. Pelanda, T. Martin, C. Degott, H. Kikutani, K. Rajewsky, J. L. Pasquali, et al. 1999. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 10: 451-461.
26. Chaplin, D. D., and Y. Fu. 1998. Cytokine regulation of secondary lymphoid organ development. Curr. Opin. Immunol. 10: 289-297.
27. Xu, H., X. Li, D. Liu, J. Li, X. Zhang, X. Chen, S. Hou, L. Peng, C. Xu, W. Liu, et al. 2013. Follicular T-helper cell recruitment governed by bystander B cells and ICOS-driven motility. Nature 496: 523-527.
28. Qi, H., J. L. Cannons, F. Klauschen, P. L. Schwartzberg, and R. N. Germain. 2008. SAP-controlled T-B cell interactions underlie germinal centre formation. Nature 455: 764-769.
29. Mandik-Nayak, L., J. Racz, B. P. Sleckman, and P. M. Allen. 2006. Autoreactive marginal zone B cells are spontaneously activated but lymph node B cells require T cell help. J. Exp. Med. 203: 1985-1998.
30. Goodnow, C. C. J., J. Crosbie, S. Adelstein, T. B. Lavoie, S. J. Smith-Gill, R. A. Brink, H. Pritchard-Briscoe, J. S. Wotherspoon, R. H. Loblay, K. Raphael, et al. 1988. Altered immunoglobulin expression and functional silencing of selfreactive B lymphocytes in transgenic mice. Nature 334: 676-682.
31. Mellor, A. L., B. Baban, P. Chandler, B. Marshall, K. Jhaver, A. Hansen, P. A. Koni, M. Iwashima, and D. H. Munn. 2003. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J. Immunol. 171: 1652-1655.
32. Baban, B., A. M. Hansen, P. R. Chandler, A. Manlapat, A. Bingaman, D. J. Kahler, D. H. Munn, and A. L. Mellor. 2005. A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. Int. Immunol. 17: 909-919.
33. Sharma, M. D., B. Baban, P. Chandler, D. Y. Hou, N. Singh, H. Yagita, M. Azuma, B. R. Blazar, A. L. Mellor, and D. H. Munn. 2007. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J. Clin. Invest. 117: 2570-2582.
34. Muller, A. J., M. D. Sharma, P. R. Chandler, J. B. Duhadaway, M. E. Everhart, B. A. Johnson, III, D. J. Kahler, J. Pihkala, A. P. Soler, D. H. Munn, et al. 2008. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc. Natl. Acad. Sci. USA 105: 17073-17078.
35. Munn, D. H., M. D. Sharma, D. Hou, B. Baban, J. R. Lee, S. J. Antonia, J. L. Messina, P. Chandler, P. A. Koni, and A. L. Mellor. 2004. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 114: 280-290.
36. Rubtsov, A. V., K. Rubtsova, A. Fischer, R. T. Meehan, J. Z. Gillis, J. W. Kappler, and P. Marrack. 2011. Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c? B-cell population is important for the development of autoimmunity. Blood 118: 1305-1315.
37. Rubtsov, A. V., K. Rubtsova, J. W. Kappler, and P. Marrack. 2013. TLR7 drives accumulation of ABCs and autoantibody production in autoimmune-prone mice. Immunol. Res. 55: 210-216.
38. Rubtsov, A. V., K. Rubtsova, J. W. Kappler, J. Jacobelli, R. S. Friedman, and P. Marrack. 2015. CD11c-Expressing B Cells Are Located at the T Cell/B Cell Border in Spleen and Are Potent APCs. J. Immunol. 195: 71-79.
39. Szczepanik, M., M. Akahira-Azuma, K. Bryniarski, R. F. Tsuji, I. Kawikova, W. Ptak, C. Kiener, R. A. Campos, and P. W. Askenase. 2003. B-1 B cells mediate required early T cell recruitment to elicit protein-induced delayedtype hypersensitivity. J. Immunol. 171: 6225-6235.
40. Tsuji, R. F., M. Szczepanik, I. Kawikova, V. Paliwal, R. A. Campos, A. Itakura, M. Akahira-Azuma, N. Baumgarth, L. A. Herzenberg, and P.W. Askenase. 2002. B cell-dependent T cell responses: IgM antibodies are required to elicit contact sensitivity. J. Exp. Med. 196: 1277-1290.
41. Crotty, S. 2011. Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 29: 621-663.
42. Taylor, M. W., and G. S. Feng. 1991. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 5: 2516-2522.
43. Munn, D. H., E. Shafizadeh, J. T. Attwood, I. Bondarev, A. Pashine, and A. L. Mellor. 1999. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 189: 1363-1372.
44. Prendergast, G. C., R. Metz, A. J. Muller, L. M. Merlo, and L. Mandik-Nayak. 2014. IDO2 in Immunomodulation and Autoimmune Disease. Front. Immunol. 5: 585.
45. Lund, F. E. 2008. Cytokine-producing B lymphocytes-key regulators of immunity. Curr. Opin. Immunol. 20: 332-338.
46. Luu, V. P., M. I. Vazquez, and A. Zlotnik. 2014. B cells participate in tolerance and autoimmunity through cytokine production. Autoimmunity 47: 1-12.
47. O'Neill, S. K., M. J. Shlomchik, T. T. Glant, Y. Cao, P. D. Doodes, and A. Finnegan. 2005. Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis. J. Immunol. 174: 3781-3788.
48. Youinou, P., S. Hillion, C. Jamin, J. O. Pers, A. Saraux, and Y. Renaudineau. 2006. B lymphocytes on the front line of autoimmunity. Autoimmun. Rev. 5: 215-221.
49. Lanzavecchia, A. 1985. Antigen-specific interaction between T and B cells. Nature 314: 537-539.
50. Chen, X., and P. E. Jensen. 2008. The role of B lymphocytes as antigenpresenting cells. Arch. Immunol. Ther. Exp. (Warsz.) 56: 77-83.
51. Watanabe, R., M. Fujimoto, N. Ishiura, Y. Kuwano, H. Nakashima, N. Yazawa, H. Okochi, S. Sato, T. F. Tedder, and K. Tamaki. 2007. CD19 expression in B cells is important for suppression of contact hypersensitivity. Am. J. Pathol. 171: 560-570.
52. Itakura, A., M. Szczepanik, R. A. Campos, V. Paliwal, M. Majewska, H. Matsuda, K. Takatsu, and P. W. Askenase. 2005. An hour after immunization peritoneal B-1 cells are activated to migrate to lymphoid organs where within 1 day they produce IgM antibodies that initiate elicitation of contact sensitivity. J. Immunol. 175: 7170-7178.
53. Tsuji, R. F., I. Kawikova, R. Ramabhadran, M. Akahira-Azuma, D. Taub, T. E. Hugli, C. Gerard, and P. W. Askenase. 2000. Early local generation of C5a initiates the elicitation of contact sensitivity by leading to early T cell recruitment. J. Immunol. 165: 1588-1598.
54. Kawai, T., and S. Akira. 2007. Signaling to NF-kappaB by Toll-like receptors. Trends Mol. Med. 13: 460-469.
55. Brown, J., H. Wang, G. N. Hajishengallis, and M. Martin. 2011. TLR-signaling networks: an integration of adaptor molecules, kinases, and cross-talk. J. Dent. Res. 90: 417-427.
56. Fischer, M., and M. Ehlers. 2008. Toll-like receptors in autoimmunity. Ann. N. Y. Acad. Sci. 1143: 21-34.
57. Sharma, S., K. A. Fitzgerald, M. P. Cancro, and A. Marshak-Rothstein. 2015. Nucleic Acid-Sensing Receptors: Rheostats of Autoimmunity and Autoinflammation. J. Immunol. 195: 3507-3512.
58. Klinman, D. M., A. K. Yi, S. L. Beaucage, J. Conover, and A. M. Krieg. 1996. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc. Natl. Acad. Sci. USA 93: 2879-2883.